Vibrio Cholerae Toxin B Subunit
The recombinant B subunit of cholera toxin (CTB) is an immunogenic component included in oral cholera vaccines (e.g., Dukoral) that stimulates specific antibodies against the toxin binding subunit, blocking cholera toxin interaction with intestinal GM1 ganglioside receptors. CTB also cross-reacts immunologically with heat-labile enterotoxin of enterotoxigenic E. coli (ETEC), providing partial protection against traveler's diarrhea. It serves as both a vaccine antigen and a mucosal adjuvant that enhances immune responses to co-administered antigens.
Mecanismo de acción
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The recombinant B subunit of cholera toxin (CTB) is an immunogenic component included in oral cholera vaccines (e.g., Dukoral) that stimulates specific antibodies against the toxin binding subunit, blocking cholera toxin interaction with intestinal GM1 ganglioside receptors. CTB also cross-reacts immunologically with heat-labile enterotoxin of enterotoxigenic E. coli (ETEC), providing partial protection against traveler's diarrhea. It serves as both a vaccine antigen and a mucosal adjuvant that enhances immune responses to co-administered antigens.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Vibrio Cholerae Toxin B Subunit is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068352. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vibrio-cholerae-toxin-b-subunit"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vibrio-cholerae-toxin-b-subunit/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vibrio-cholerae-toxin-b-subunit/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vibrio-cholerae-toxin-b-subunit/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vibrio-cholerae-toxin-b-subunit"></drugfyi-drug>